{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:07:47Z","timestamp":1766167667256,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03631-1","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:25:50Z","timestamp":1750393550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod"],"prefix":"10.1007","volume":"45","author":[{"given":"Ali Mert","family":"Ko\u00e7er","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6zde","family":"Hondur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Murat","family":"Uzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u0131nar","family":"K\u00f6sekahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysel","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00fcbra \u00d6zdemir","family":"Yal\u00e7\u0131nsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"2","key":"3631_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/00055735-199604000-00014","volume":"7","author":"C Baudouin","year":"1996","unstructured":"Baudouin C (1996) Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 7(2):80\u201386","journal-title":"Curr Opin Ophthalmol"},{"key":"3631_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40265-018-0914-6","volume":"7","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Latanoprostene bunod ophthalmic solution 0.024%: a review in open-angle glaucoma and ocular hypertension. Drugs 7:773\u2013780","journal-title":"Drugs"},{"issue":"11","key":"3631_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s12325-015-0260-y","volume":"32","author":"M Araie","year":"2015","unstructured":"Araie M, Sforzolini BS, Vittitow J, Weinreb RN (2015) Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther 32(11):1128\u20131139","journal-title":"Adv Ther"},{"issue":"1","key":"3631_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/joco.joco_173_21","volume":"34","author":"M Pakbin","year":"2022","unstructured":"Pakbin M, Khabazkhoob M, Pakravan M, Fotouhi A, Jafarzadehpur E, Aghamirsalim M, Hashemi H (2022) Repeatability of corneal densitometry measurements using a scheimpflug camera in healthy normal corneas. J Curr Ophthalmol 34(1):50\u201355","journal-title":"J Curr Ophthalmol"},{"issue":"1","key":"3631_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.survophthal.2024.09.007","volume":"70","author":"Q Yang","year":"2025","unstructured":"Yang Q, Ju G, He Y (2025) Corneal densitometry: a new evaluation indicator for corneal diseases. Surv Ophthalmol 70(1):132\u2013140","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"3631_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/IJG.0000000000000190","volume":"25","author":"WA Schrems","year":"2016","unstructured":"Schrems WA, Schrems-Hoesl LM, Mardin CY, Horn FK, Juenemann AG, Kruse FE, Braun JM, Laemmer R (2016) The effect of long-term antiglaucomatous drug administration on central corneal thickness. J Glaucoma 25(3):274\u2013280","journal-title":"J Glaucoma"},{"issue":"2","key":"3631_CR7","first-page":"120","volume":"35","author":"M Uematsu","year":"2016","unstructured":"Uematsu M, Mohamed YH, Onizuka N, Ueki R, Inoue D, Fujikawa A, Sasaki H, Kitaoka T (2016) Acute corneal toxicity of latanoprost with different preservatives. Cutan Ocul Toxicol 35(2):120\u2013125","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"3631_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3346\/jkms.2002.17.3.389","volume":"17","author":"JC Kim","year":"2002","unstructured":"Kim JC, Park GS, Kim JK, Kim YM (2002) The role of nitric oxide in ocular surface cells. J Korean Med Sci 17(3):389\u2013394","journal-title":"J Korean Med Sci"},{"issue":"3","key":"3631_CR9","first-page":"713","volume":"42","author":"WJ O\u2019Brien","year":"2001","unstructured":"O\u2019Brien WJ, Heimann T, Tsao LS, Seet BT, McFadden G, Taylor JL (2001) Regulation of nitric oxide synthase 2 in rabbit corneal cells. Invest Ophthalmol Vis Sci 42(3):713\u2013719","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"3631_CR10","first-page":"1711","volume":"37","author":"FF Behar-Cohen","year":"1996","unstructured":"Behar-Cohen FF, Goureau O, D\u2019Hermies F, Courtois Y (1996) Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest Ophthalmol Vis Sci 37(8):1711\u20131715","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3631_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2013.03.070","volume":"62","author":"C Napoli","year":"2013","unstructured":"Napoli C, Paolisso G, Casamassimi A, Al-Omran M, Barbieri M, Sommese L, Infante T, Ignarro LJ (2013) Effects of nitric oxide on cell proliferation: novel insights. J Am Coll Cardiol 62(2):89\u201395","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3631_CR12","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1038\/s41598-017-08576-9","volume":"7","author":"JH Park","year":"2017","unstructured":"Park JH, Kim JY, Kim DJ, Kim M, Chang M, Chuck RS, Park CY (2017) Effect of nitric oxide on human corneal epithelial cell viability and corneal wound healing. Sci Rep 7(1):8093","journal-title":"Sci Rep"},{"issue":"11","key":"3631_CR13","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1167\/iovs.04-0439","volume":"45","author":"P Sagoo","year":"2004","unstructured":"Sagoo P, Chan G, Larkin DF, George AJ (2004) Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Invest Ophthalmol Vis Sci 45(11):3964\u20133973","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3631_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2008.03.020","volume":"45","author":"DD Thomas","year":"2008","unstructured":"Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA (2008) The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 45(1):18\u201331","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"3631_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/ICL.0b013e318159b009","volume":"34","author":"W Wang","year":"2008","unstructured":"Wang W, Xue M, Willcox M, Thakur A (2008) Role of nitric oxide in P. aeruginosa keratitis caused by distinct bacterial phenotypes. Eye Contact Lens 34(4):195\u2013197","journal-title":"Eye Contact Lens"},{"issue":"6","key":"3631_CR16","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.exer.2006.07.014","volume":"83","author":"V Bonfiglio","year":"2006","unstructured":"Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F (2006) Effects of the COOH-terminal tripeptide alpha-MSH(11\u201313) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 83(6):1366\u20131372","journal-title":"Exp Eye Res"},{"issue":"5","key":"3631_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1006\/niox.1997.0145","volume":"1","author":"N Yanagiya","year":"1997","unstructured":"Yanagiya N, Akiba J, Kado M, Yoshida A, Kono T, Iwamoto J (1997) Transient corneal edema induced by nitric oxide synthase inhibition. Nitric Oxide 1(5):397\u2013403","journal-title":"Nitric Oxide"},{"issue":"4","key":"3631_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","volume":"18","author":"PL Kaufman","year":"2017","unstructured":"Kaufman PL (2017) Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother 18(4):433\u2013444","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"3631_CR19","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1167\/iovs.14-14515","volume":"55","author":"ME Cavet","year":"2014","unstructured":"Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E (2014) Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci 55(8):5005\u20135015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"3631_CR20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","volume":"99","author":"RN Weinreb","year":"2015","unstructured":"Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL (2015) VOYAGER study group A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 99(6):738\u2013745","journal-title":"Br J Ophthalmol"},{"key":"3631_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ajo.2016.05.012","volume":"168","author":"FA Medeiros","year":"2016","unstructured":"Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN (2016) Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The LUNAR study. Am J Ophthalmol 168:250\u2013259","journal-title":"Am J Ophthalmol"},{"issue":"15","key":"3631_CR22","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.3390\/jcm11154325","volume":"11","author":"TC Lo","year":"2022","unstructured":"Lo TC, Chen YY, Hung MC, Chou P (2022) Latanoprostene bunod 0.024% in the treatment of open-angle glaucoma and ocular hypertension: a meta-analysis. J Clin Med 11(15):4325","journal-title":"J Clin Med"},{"issue":"12","key":"3631_CR23","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1167\/iovs.02-0462","volume":"44","author":"H Mietz","year":"2003","unstructured":"Mietz H, Esser JM, Welsandt G, Kociok N, Hueber A, Joussen A, Esser P, Krieglstein GK (2003) Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci 44(12):5182\u20135188","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"3631_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.ijg.0000212210.33265.24","volume":"15","author":"Y Liu","year":"2006","unstructured":"Liu Y, Yanai R, Lu Y, Hirano S, Sagara T, Nishida T (2006) Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblast. J Glaucoma 15(3):255\u2013259","journal-title":"J Glaucoma"},{"issue":"3","key":"3631_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/15569527.2019.1590390","volume":"38","author":"E Sen","year":"2019","unstructured":"Sen E, Inanc M, Elgin U (2019) The effect of topical latanoprost on corneal clarity; 1-year prospective study. Cutan Ocul Toxicol 38(3):253\u2013257","journal-title":"Cutan Ocul Toxicol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03631-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:02:57Z","timestamp":1766167377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03631-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03631-1","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"252"}}